Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison and Strategy Optimization of Plasma Epstein-Barr Virus (EBV) DNA and BNLF2b Total Antibodies (P85-Ab) with VCA-IgA and EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

NCT06870435 is registered in ClinicalTrials.gov with Ming-Yuan Chen as lead sponsor.

NCT NCT06870435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06870435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison and Strategy Optimization of Plasma Epstein-Barr Virus (EBV) DNA and BNLF2b Total Antibodies (P85-Ab) with VCA-IgA and EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Lead sponsor
Ming-Yuan Chen
Phase
Not applicable
Overall status
Recruiting
Start date
January 24, 2025
Completion date
December 31, 2035
Enrollment
68,649 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein barr virus, nasopharyngeal carcinoma (npc), screening